Last reviewed · How we verify
Apixaban 2.5 milligram
Apixaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.
Apixaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.
At a glance
| Generic name | Apixaban 2.5 milligram |
|---|---|
| Also known as | medication adherence assessment |
| Sponsor | McMaster University |
| Drug class | Direct Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Apixaban selectively inhibits Factor Xa, a serine protease critical in both the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa activity, it prevents the generation of thrombin and subsequent fibrin clot formation, thereby reducing thrombotic events. This direct mechanism allows for predictable anticoagulation without requiring monitoring.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis (DVT) treatment and prevention
- Pulmonary embolism (PE) treatment and prevention
- Thromboprophylaxis after hip or knee replacement surgery
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Nausea
- Syncope
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apixaban 2.5 milligram CI brief — competitive landscape report
- Apixaban 2.5 milligram updates RSS · CI watch RSS
- McMaster University portfolio CI